vs

Side-by-side financial comparison of Hillman Solutions Corp. (HLMN) and MADRIGAL PHARMACEUTICALS, INC. (MDGL). Click either name above to swap in a different company.

Hillman Solutions Corp. is the larger business by last-quarter revenue ($370.1M vs $321.1M, roughly 1.2× MADRIGAL PHARMACEUTICALS, INC.). Hillman Solutions Corp. runs the higher net margin — -1.3% vs -18.2%, a 17.0% gap on every dollar of revenue. On growth, MADRIGAL PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (210.8% vs 3.0%). Hillman Solutions Corp. produced more free cash flow last quarter ($-34.3M vs $-133.8M).

Hillman Solutions is an American hardware manufacturing, distribution and consumer fabrication services company.

Intercept Pharmaceuticals, Inc. is an American biopharmaceutical company incorporated in 2002, focusing on the development of novel synthetic bile acid analogs to treat chronic liver diseases, such as primary biliary cirrhosis (PBC) now called primary biliary cholangitis, non-alcoholic fatty liver disease, cirrhosis, portal hypertension, primary sclerosing cholangitis and also the intestinal disorder, bile acid diarrhea.

HLMN vs MDGL — Head-to-Head

Bigger by revenue
HLMN
HLMN
1.2× larger
HLMN
$370.1M
$321.1M
MDGL
Growing faster (revenue YoY)
MDGL
MDGL
+207.8% gap
MDGL
210.8%
3.0%
HLMN
Higher net margin
HLMN
HLMN
17.0% more per $
HLMN
-1.3%
-18.2%
MDGL
More free cash flow
HLMN
HLMN
$99.5M more FCF
HLMN
$-34.3M
$-133.8M
MDGL

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
HLMN
HLMN
MDGL
MDGL
Revenue
$370.1M
$321.1M
Net Profit
$-4.7M
$-58.6M
Gross Margin
Operating Margin
1.9%
-18.6%
Net Margin
-1.3%
-18.2%
Revenue YoY
3.0%
210.8%
Net Profit YoY
1.4%
EPS (diluted)
$-0.02
$-2.55

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
HLMN
HLMN
MDGL
MDGL
Q1 26
$370.1M
Q4 25
$365.1M
$321.1M
Q3 25
$424.9M
$287.3M
Q2 25
$402.8M
$212.8M
Q1 25
$359.3M
$137.3M
Q4 24
$349.6M
$103.3M
Q3 24
$393.3M
$62.2M
Q2 24
$379.4M
Net Profit
HLMN
HLMN
MDGL
MDGL
Q1 26
$-4.7M
Q4 25
$1.6M
$-58.6M
Q3 25
$23.2M
$-114.2M
Q2 25
$15.8M
$-42.3M
Q1 25
$-317.0K
$-73.2M
Q4 24
$-1.2M
$-59.4M
Q3 24
$7.4M
$-107.0M
Q2 24
$12.5M
Gross Margin
HLMN
HLMN
MDGL
MDGL
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
96.7%
Q4 24
Q3 24
Q2 24
Operating Margin
HLMN
HLMN
MDGL
MDGL
Q1 26
1.9%
Q4 25
4.6%
-18.6%
Q3 25
10.8%
-39.7%
Q2 25
9.0%
-22.2%
Q1 25
4.2%
-57.8%
Q4 24
4.0%
-64.8%
Q3 24
6.8%
-187.1%
Q2 24
8.3%
Net Margin
HLMN
HLMN
MDGL
MDGL
Q1 26
-1.3%
Q4 25
0.4%
-18.2%
Q3 25
5.5%
-39.8%
Q2 25
3.9%
-19.9%
Q1 25
-0.1%
-53.4%
Q4 24
-0.3%
-57.5%
Q3 24
1.9%
-172.0%
Q2 24
3.3%
EPS (diluted)
HLMN
HLMN
MDGL
MDGL
Q1 26
$-0.02
Q4 25
$0.00
$-2.55
Q3 25
$0.12
$-5.08
Q2 25
$0.08
$-1.90
Q1 25
$0.00
$-3.32
Q4 24
$-0.00
$-2.50
Q3 24
$0.04
$-4.92
Q2 24
$0.06

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
HLMN
HLMN
MDGL
MDGL
Cash + ST InvestmentsLiquidity on hand
$27.7M
$198.7M
Total DebtLower is stronger
$714.1M
$339.9M
Stockholders' EquityBook value
$1.2B
$602.7M
Total Assets
$2.4B
$1.3B
Debt / EquityLower = less leverage
0.59×
0.56×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
HLMN
HLMN
MDGL
MDGL
Q1 26
$27.7M
Q4 25
$27.3M
$198.7M
Q3 25
$37.7M
$295.7M
Q2 25
$34.2M
$186.2M
Q1 25
$36.3M
$183.6M
Q4 24
$44.5M
$100.0M
Q3 24
$59.8M
$232.7M
Q2 24
$54.0M
Total Debt
HLMN
HLMN
MDGL
MDGL
Q1 26
$714.1M
Q4 25
$668.3M
$339.9M
Q3 25
$683.2M
$339.8M
Q2 25
$683.1M
$118.4M
Q1 25
$713.5M
$118.0M
Q4 24
$691.7M
$117.6M
Q3 24
$730.7M
$117.1M
Q2 24
$732.1M
Stockholders' Equity
HLMN
HLMN
MDGL
MDGL
Q1 26
$1.2B
Q4 25
$1.2B
$602.7M
Q3 25
$1.2B
$625.7M
Q2 25
$1.2B
$696.0M
Q1 25
$1.2B
$710.6M
Q4 24
$1.2B
$754.4M
Q3 24
$1.2B
$777.2M
Q2 24
$1.2B
Total Assets
HLMN
HLMN
MDGL
MDGL
Q1 26
$2.4B
Q4 25
$2.4B
$1.3B
Q3 25
$2.4B
$1.4B
Q2 25
$2.4B
$1.0B
Q1 25
$2.3B
$996.6M
Q4 24
$2.3B
$1.0B
Q3 24
$2.4B
$1.1B
Q2 24
$2.4B
Debt / Equity
HLMN
HLMN
MDGL
MDGL
Q1 26
0.59×
Q4 25
0.54×
0.56×
Q3 25
0.56×
0.54×
Q2 25
0.57×
0.17×
Q1 25
0.60×
0.17×
Q4 24
0.59×
0.16×
Q3 24
0.62×
0.15×
Q2 24
0.62×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
HLMN
HLMN
MDGL
MDGL
Operating Cash FlowLast quarter
$-133.5M
Free Cash FlowOCF − Capex
$-34.3M
$-133.8M
FCF MarginFCF / Revenue
-9.3%
-41.7%
Capex IntensityCapex / Revenue
4.0%
0.1%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$22.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
HLMN
HLMN
MDGL
MDGL
Q1 26
Q4 25
$30.9M
$-133.5M
Q3 25
$26.2M
$79.8M
Q2 25
$48.7M
$-47.1M
Q1 25
$-655.0K
$-88.9M
Q4 24
$43.1M
$-104.5M
Q3 24
$63.7M
$-67.0M
Q2 24
$64.8M
Free Cash Flow
HLMN
HLMN
MDGL
MDGL
Q1 26
$-34.3M
Q4 25
$16.1M
$-133.8M
Q3 25
$9.1M
$79.0M
Q2 25
$31.2M
Q1 25
$-21.3M
Q4 24
$22.1M
$-104.7M
Q3 24
$39.6M
$-67.8M
Q2 24
$42.5M
FCF Margin
HLMN
HLMN
MDGL
MDGL
Q1 26
-9.3%
Q4 25
4.4%
-41.7%
Q3 25
2.1%
27.5%
Q2 25
7.7%
Q1 25
-5.9%
Q4 24
6.3%
-101.3%
Q3 24
10.1%
-109.0%
Q2 24
11.2%
Capex Intensity
HLMN
HLMN
MDGL
MDGL
Q1 26
4.0%
Q4 25
4.0%
0.1%
Q3 25
4.0%
0.3%
Q2 25
4.3%
0.0%
Q1 25
5.7%
0.0%
Q4 24
6.0%
0.2%
Q3 24
6.1%
1.3%
Q2 24
5.9%
Cash Conversion
HLMN
HLMN
MDGL
MDGL
Q1 26
Q4 25
19.33×
Q3 25
1.13×
Q2 25
3.08×
Q1 25
Q4 24
Q3 24
8.57×
Q2 24
5.17×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

HLMN
HLMN

Segment breakdown not available.

MDGL
MDGL

Rebates Customer Fees Credits Co Pay Assistance And Other$208.5M65%
Other$76.0M24%
Chargebacks Discounts For Prompt Pay And Other Allowances$36.6M11%

Related Comparisons